Cosmo Pharmaceuticals N.V. (0RGI.L)

66,49 +1,49 (+2,30%) Al 05:34PM GMT. Mercato aperto.

Cosmo Pharmaceuticals N.V.

Riverside II
Sir John Rogerson’s Quay
Dublin 2
Ireland
353 1 817 0370
https://www.cosmopharma.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 292

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Mauro Severino Ajani	Founder & Exec. Chairman	435,5k	N/D	1955
Mr. Alessandro E. Della Cha LL.M	CEO & Exec. Director	659,95k	N/D	1963
Mr. Ngo Dinh Nhan	Head of R&D - AI & Biomedical IT	N/D	N/D	1979
Mr. Giulio Evangelisti	Head of Production, AI & Biomedical IT	N/D	N/D	1970
Mr. Niall Donnelly	Chief Financial Officer	N/D	N/D	1972
Mr. Marco Lecchi	Chief Operating Officer	N/D	N/D	1964
Mr. Davide Malavasi	Qualified Person & Technical Director	N/D	N/D	1973
Mr. Luigi Longo	Chief Scientific Officer	N/D	N/D	1979
Ms. Hazel Winchester	Head of Investor Relations	N/D	N/D	1971
Mr. Biagio Vigano	Chief People Officer	N/D	N/D	1974

Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CHF.

Descrizione

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Governance aziendale

L'ISS Governance QualityScore di Cosmo Pharmaceuticals N.V. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.